Related Experiment Video
Updated: May 8, 2026
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
C Heise1, T Hermiston, L Johnson
1Chiron Corporation, Emeryville, California, USA.
Abstract:
Replication-selective oncolytic viruses constitute a rapidly evolving and new treatment platform for cancer. Gene-deleted viruses have been engineered for tumor selectivity, but these gene deletions also reduce the anti-cancer potency of the viruses. We have identified an E1A mutant adenovirus, dl922-947, that replicates in and lyses a broad range of cancer cells with abnormalities in cell-cycle checkpoints. This mutant demonstrated reduced S-phase induction and replication in non-proliferating normal cells, and superior in vivo potency relative to other gene-deleted adenoviruses. In some cancers, its potency was superior to even wild-type adenovirus. Intravenous administration reduced the incidence of metastases in a breast tumor xenograft model. dl922-947 holds promise as a potent, replication-selective virus for the local and systemic treatment of cancer.
Insights
A novel adenovirus mutant, dl922-947, effectively targets and destroys cancer cells while sparing normal cells. This replication-selective oncolytic virus shows significant potential for treating various cancers, reducing metastasis, and improving patient outcomes.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Oncolytic viruses are an emerging cancer treatment strategy.
- Engineered gene-deleted viruses offer tumor selectivity but reduced potency.
- Novel approaches are needed to enhance oncolytic virus efficacy and safety.
Purpose of the Study:
- To identify and characterize a novel replication-selective oncolytic adenovirus with enhanced anti-cancer potency.
- To evaluate the tumor selectivity and in vivo efficacy of the E1A mutant adenovirus dl922-947.
- To assess the potential of dl922-947 for both local and systemic cancer treatment.
Main Methods:
- Engineering of an E1A mutant adenovirus (dl922-947) with impaired replication in normal cells.
- In vitro assessment of viral replication and cancer cell lysis in cancer cell lines with cell-cycle checkpoint abnormalities.
- In vivo evaluation of dl922-947 efficacy in a breast tumor xenograft model, including assessment of metastasis reduction.
Main Results:
- The dl922-947 mutant demonstrated selective replication and lysis of cancer cells with cell-cycle defects.
- Reduced S-phase induction and replication were observed in non-proliferating normal cells.
- Superior in vivo anti-cancer potency was observed compared to other gene-deleted adenoviruses and, in some cases, wild-type adenovirus.
- Intravenous administration of dl922-947 reduced metastasis incidence in a preclinical model.
Conclusions:
- The E1A mutant adenovirus dl922-947 is a potent, replication-selective oncolytic virus.
- dl922-947 exhibits enhanced tumor selectivity and efficacy, offering a promising therapeutic candidate.
- This novel oncolytic virus holds potential for local and systemic cancer treatment, including reducing metastatic spread.
